---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-026156"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:25:44.733521+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Founder Berns becomes CEO as Gosebruch departs; option repricing approved

## Summary
- Paul L. Berns transitions from executive chair to CEO & chairman, effective Feb 14, 2025.
- CEO Henry Gosebruch and Chief Commercial Officer Kaya Pai Panandiker leave the company.
- Joshua Pinto promoted to president (base $645k, 60% target bonus, $970k signing bonus, 3M option).
- Bill Aurora becomes COO & CDO; Michael Milligan becomes CFO; other leadership changes announced.
- Board approved option repricing subject to stockholder approval; exercise price set at Feb 13 closing price.

## SEC filing metadata
- accession: 0001193125-25-026156
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/d932957d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-026156
- JSON: https://secwatch.observer/filing/0001193125-25-026156.json
- Plain text: https://secwatch.observer/filing/0001193125-25-026156.txt

## Key facts
- Executive change
  Joshua Pinto changed role as President at Neumora Therapeutics, Inc..
  - Action: transitioned
  - Role: President
  source text: Joshua Pinto, Ph.D. will transition from the role of Chief Financial Officer to President
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm
- Executive change
  Henry Gosebruch departed as President, Chief Executive Officer at Neumora Therapeutics, Inc..
  - Action: departed
  - Role: President, Chief Executive Officer
  source text: Henry Gosebruch will depart the Company and no longer serve as President, Chief Executive Officer or a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm
- Executive change
  Carol Suh changed role as Chief Strategy Officer at Neumora Therapeutics, Inc..
  - Action: transitioned
  - Role: Chief Strategy Officer
  source text: Carol Suh will transition from the role of Chief Operating Officer to Chief Strategy Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm
- Executive change
  Bill Aurora changed role as Chief Operating and Development Officer at Neumora Therapeutics, Inc..
  - Action: transitioned
  - Role: Chief Operating and Development Officer
  source text: Bill Aurora, Pharm.D. will transition from the role of Chief Strategy Officer to Chief Operating and Development Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm
- Executive change
  Jason Duncan was appointed as Chief Legal and Administrative Officer at Neumora Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Legal and Administrative Officer
  source text: Jason Duncan will serve as Chief Legal and Administrative Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm
- Executive change
  Kaya Pai Panandiker departed as Chief Commercial Officer at Neumora Therapeutics, Inc..
  - Action: departed
  - Role: Chief Commercial Officer
  source text: Kaya Pai Panandiker will depart the Company and no longer serve as Chief Commercial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm
- Executive change
  Michael Milligan was appointed as Chief Financial Officer at Neumora Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Michael Milligan will serve as Chief Financial Officer in addition to his current role as principal accounting officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm
- Executive change
  Paul L. Berns changed role as Chief Executive Officer and Chairman of the Board at Neumora Therapeutics, Inc..
  - Action: transitioned
  - Role: Chief Executive Officer and Chairman of the Board
  source text: Paul L. Berns, the Company’s Co-Founder and Executive Chairman of its Board of Directors (the “Board”), will transition to the roles of Chief Executive Officer and Chairman of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.